Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Alterity Therapeutics stock price, quote, forecast and news

ATH.AX
AU0000043945
A2PHDZ

Price

0.00
Today +/-
+0
Today %
+0 %
P

Alterity Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Alterity Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Alterity Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Alterity Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Alterity Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Alterity Therapeutics Stock Price History

DateAlterity Therapeutics Price
9/24/20240.00 undefined
9/23/20240.00 undefined
9/20/20240.00 undefined
9/19/20240.00 undefined
9/18/20240.00 undefined
9/17/20240.00 undefined
9/16/20240.00 undefined
9/13/20240.00 undefined
9/12/20240.00 undefined
9/11/20240.00 undefined
9/10/20240.00 undefined
9/9/20240.00 undefined
9/6/20240.00 undefined
9/5/20240.00 undefined
9/4/20240.00 undefined
9/3/20240.00 undefined
9/2/20240.00 undefined
8/30/20240.00 undefined
8/29/20240.00 undefined
8/28/20240.00 undefined
8/27/20240.00 undefined

Alterity Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Alterity Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Alterity Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Alterity Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Alterity Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Alterity Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Alterity Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Alterity Therapeutics’s growth potential.

Alterity Therapeutics Revenue, EBIT and net profit per share

DateAlterity Therapeutics RevenueAlterity Therapeutics EBITAlterity Therapeutics Net Income
2024268,420 undefined-19.34 M undefined-19.12 M undefined
202316,440 undefined-14.62 M undefined-13.81 M undefined
20222,500 undefined-15.95 M undefined-12.85 M undefined
202120,680 undefined-15.37 M undefined-15.31 M undefined
202017,120 undefined-13.91 M undefined-13.46 M undefined
2019108,540 undefined-12.69 M undefined-12.34 M undefined
2018201,170 undefined-7.99 M undefined-8.27 M undefined
2017132,400 undefined-6.88 M undefined-7.54 M undefined
2016142,660 undefined-8.59 M undefined-7.73 M undefined
2015176,840 undefined-17.01 M undefined-5.89 M undefined
2014360,000 undefined-20.37 M undefined-13.33 M undefined
2013150,000 undefined-12.27 M undefined-7.79 M undefined
2012190,000 undefined-5.31 M undefined-5.24 M undefined
2011160,000 undefined-6.27 M undefined-6.43 M undefined
2010220,000 undefined-4.9 M undefined-4.91 M undefined
2009430,000 undefined-8.29 M undefined-7.53 M undefined
2008490,000 undefined-12.71 M undefined-13.56 M undefined
2007510,000 undefined-10.99 M undefined-11.14 M undefined
20061.05 M undefined-11.94 M undefined-11.72 M undefined
20052.65 M undefined-12.79 M undefined-25.01 M undefined

Alterity Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
000001221000000000000000000
------100.00--50.00------------------
---------------------------
000000000000000000000003430
00-1-4-5-4-9-12-11-10-12-8-4-6-5-12-20-17-8-6-7-12-13-15-15-14-19
------400.00-450.00-600.00-1,100.00------------------
00-1-4-5-4-9-25-11-11-13-7-4-6-5-7-13-5-7-7-8-12-13-15-12-13-19
---300.0025.00-20.00125.00177.78-56.00-18.18-46.15-42.8650.00-16.6740.0085.71-61.5440.00-14.2950.008.3315.38-20.008.3346.15
0.030.030.040.050.060.060.080.120.130.140.170.20.230.250.290.340.430.50.530.530.530.620.891.72.412.433.68
---------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Alterity Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Alterity Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                 
04.476.863.593.4629.5821.4510.067.4611.234.315.238.845.6413.3534.17028.5921.8815.2414.49.228.1234.8115.77
000000000000000004.793.043.154.830.01008.65
0000000000000000000000.054.284.730.02
0000000000000000000000000
00.320.170.060.050.070.570.070.120.240.190.070.090.070.110.060.160.280.330.270.630.581.11.612.61
04.797.033.653.5129.6522.0210.137.5811.474.55.38.935.7113.4634.230.1633.6625.2518.6519.869.8433.4941.1427.05
2001601501401401801701005070706040505050024.2330.8271.4248.7571.3796.81218.52269
0000000000000000000000000
00000000000000000000001515617
1.6415.8914.7913.6912.5911.490000000000000000000
0000000000000000000000000
00000000040404040404040043.990000000
1.8416.0514.9413.8312.7311.670.170.10.050.110.110.10.080.090.090.0900.070.030.070.050.070.250.270.29
1.8420.8421.9717.4816.2441.3222.1910.237.6311.584.615.49.015.813.5534.320.1633.7325.2818.7319.919.9133.7441.4227.34
                                                 
07.4712.281316.7449.5155.4155.153.9969.8467.4972.4279.6486.13101.38140.010146.88144.02143.91156.63160.7197.45213.79213.97
00000000000000009.3600000000
-0.0813.269.123.67-0.92-10.8-35.81-46.37-48.38-59.98-66.44-69.89-75.41-80.51-87.4-102.320-115.51-120.33-127.83-140.08-153.55-166.98-178.32-195.13
00000000002.72.72.70000000002.753.573.97
0000000000000000000000000
-0.0820.7321.416.6715.8238.7119.68.735.619.863.755.236.935.6213.9837.699.3631.3723.6916.0816.557.1533.2239.0422.81
0.080.110.820.520.150.341.241.421.660.850.61.241.050.960.280.650.361.750.892.062.720.951.452.691.72
000000000000001.52.712.3400001.11.022.332.5
00.040.10.390.412.371.420.190.080.120.20.260.740.450.450.4900.610.70.590.60.620.570.740.06
0000000000000000000000000
000000000770002903008701000000032.8827.7557.63107
0.080.150.920.910.562.712.661.611.741.740.81.52.081.713.13.952.712.361.592.643.322.713.075.824.39
1.8400000000.3200000000000000.040.060.1
0000000000000000000000000
00000105080509050700100000.470.440.9234.9841.519.7713.7520
1.8400000.010.050.080.370.090.050.0700.010000000.030.040.050.070.12
1.920.150.920.910.562.722.711.692.111.830.851.572.081.723.13.952.712.361.592.643.362.763.125.894.51
1.8420.8822.3217.5816.3841.4322.3110.427.7211.694.66.89.017.3417.0841.6412.0733.7325.2818.7319.919.9136.3444.9327.32
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Alterity Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Alterity Therapeutics's financial health and stability.

Assets

Alterity Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Alterity Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Alterity Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Alterity Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20002001200220032004200520062007200820092010201120122014201520162017201820192020202120222023
0000000000000000000-13-15-12-13
00000000000000000000000
00000000000000000000000
00001200000014764334040
000000000000000000002-10
00000000000000000000000
00000000000000000000000
0-2-3-3-5-11-11-9-9-6-4-4-6-13-10-7-5-6-13-9-17-12-20
00000000000000000000000
00000000000000000000000
00000000000000000000000
00000000000000000000000
-20000000000000000000000
85033440714068337700013439170
54033140713058334600012336160
-----2.00---------1.00-------2.00--
00000000000000000000000
30-7-419-21-23-12-5-14-3-1-112-17-20-17-16-18-191-10-38
-0.97-2.36-3.85-3.68-5.48-11.47-11.71-9.21-9.44-7.03-4.73-4.57-6.88-13.56-10.9-7.27-5.89-6.31-13.96-9.45-17.34-12.43-20.04
00000000000000000000000

Alterity Therapeutics stock margins

The Alterity Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Alterity Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Alterity Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Alterity Therapeutics's sales revenue. A higher gross margin percentage indicates that the Alterity Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Alterity Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Alterity Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Alterity Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Alterity Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Alterity Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Alterity Therapeutics Margin History

Alterity Therapeutics Gross marginAlterity Therapeutics Profit marginAlterity Therapeutics EBIT marginAlterity Therapeutics Profit margin
202422,110.71 %-7,204.58 %-7,124.45 %
202322,110.71 %-88,940.45 %-83,981.27 %
2022190,200.01 %-638,144.43 %-513,882.4 %
202119,245.65 %-74,328.35 %-74,029.74 %
2020-2,061.92 %-81,265.07 %-78,602.81 %
201922,110.71 %-11,688.68 %-11,367.08 %
201822,110.71 %-3,974.19 %-4,108.83 %
201722,110.71 %-5,197.78 %-5,696.43 %
201622,110.71 %-6,019.07 %-5,418.16 %
201522,110.71 %-9,619.02 %-3,327.91 %
201422,110.71 %-5,658.33 %-3,702.78 %
201322,110.71 %-8,180 %-5,193.33 %
201222,110.71 %-2,794.74 %-2,757.89 %
201122,110.71 %-3,918.75 %-4,018.75 %
201022,110.71 %-2,227.27 %-2,231.82 %
200922,110.71 %-1,927.91 %-1,751.16 %
200822,110.71 %-2,593.88 %-2,767.35 %
200722,110.71 %-2,154.9 %-2,184.31 %
200622,110.71 %-1,137.14 %-1,116.19 %
200522,110.71 %-482.64 %-943.77 %

Alterity Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Alterity Therapeutics earnings per share therefore indicates how much revenue Alterity Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Alterity Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Alterity Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Alterity Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Alterity Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Alterity Therapeutics Revenue, EBIT and net profit per share

DateAlterity Therapeutics Sales per ShareAlterity Therapeutics EBIT per shareAlterity Therapeutics Earnings per Share
20240 undefined-0.01 undefined-0.01 undefined
20230 undefined-0.01 undefined-0.01 undefined
20220 undefined-0.01 undefined-0.01 undefined
20210 undefined-0.01 undefined-0.01 undefined
20200 undefined-0.02 undefined-0.02 undefined
20190 undefined-0.02 undefined-0.02 undefined
20180 undefined-0.01 undefined-0.02 undefined
20170 undefined-0.01 undefined-0.01 undefined
20160 undefined-0.02 undefined-0.01 undefined
20150 undefined-0.03 undefined-0.01 undefined
20140 undefined-0.05 undefined-0.03 undefined
20130 undefined-0.04 undefined-0.02 undefined
20120 undefined-0.02 undefined-0.02 undefined
20110 undefined-0.03 undefined-0.03 undefined
20100 undefined-0.02 undefined-0.02 undefined
20090 undefined-0.04 undefined-0.04 undefined
20080 undefined-0.07 undefined-0.08 undefined
20070 undefined-0.08 undefined-0.08 undefined
20060.01 undefined-0.09 undefined-0.09 undefined
20050.02 undefined-0.1 undefined-0.2 undefined

Alterity Therapeutics business model

Alterity Therapeutics Ltd is an Australian company specializing in the discovery and development of therapeutics for neurodegenerative diseases. The company's history dates back to 1997 when it was established under the name Prana Biotechnology Limited. Alterity Therapeutics' business model is based on the research of protein aggregates responsible for neurodegenerative diseases. The company primarily focuses on developing drugs targeting the breakdown of these protein aggregates to minimize the effects of diseases such as Parkinson's, Alzheimer's, and Huntington's. The company has several divisions specializing in various aspects of product development, including preclinical research, clinical development, and commercial marketing. Alterity Therapeutics has several products in various stages of development. One of its leading products is PBT434, a drug that aims to prevent protein aggregates in the brain and target the treatment of Parkinson's disease. The drug has already been tested in clinical trials and has shown promising results. In addition to PBT434, the company also has other promising drugs in development, including PBT519, targeting the treatment of Alzheimer's disease, and PBT2, targeting the treatment of Huntington's disease. Alterity Therapeutics aims to minimize the impact of neurodegenerative diseases and improve the quality of life for millions of patients worldwide. The company collaborates with leading medical and academic institutions to develop innovative therapeutics that meet the needs of patients and clinicians. Overall, Alterity Therapeutics offers a promising pipeline of drugs that could play a significant role in the treatment of neurodegenerative diseases. The company has become a major player in the industry and has the potential to make a significant impact in the fight against these serious illnesses. Alterity Therapeutics is one of the most popular companies on Eulerpool.com.

Alterity Therapeutics SWOT Analysis

Strengths

Alterity Therapeutics Ltd has a strong product portfolio with innovative drug candidates that address neurological diseases.

The company has a robust pipeline of potential treatments, ensuring future growth and expansion.

Alterity Therapeutics Ltd has a talented team of researchers and scientists with extensive experience in the pharmaceutical industry.

Weaknesses

The company is heavily reliant on the success of its drug candidates, with limited diversification in the product portfolio.

Alterity Therapeutics Ltd may face challenges in securing sufficient funding for clinical trials and research and development activities.

The company operates in a highly competitive market, which can impact its ability to gain market share.

Opportunities

The increasing prevalence of neurological diseases presents a significant opportunity for Alterity Therapeutics Ltd to capture a larger market share.

Advancements in technology and research in the field of neurology create potential for the development of breakthrough treatments.

Partnerships and collaborations with other pharmaceutical companies or research institutions can provide access to additional resources and expertise.

Threats

Regulatory challenges and the lengthy approval process for new drugs pose a threat to the timely commercialization of Alterity Therapeutics Ltd's products.

Competitors in the industry may develop similar or superior drug candidates, limiting the market potential for Alterity Therapeutics Ltd.

Changes in healthcare policies and reimbursement systems can impact the pricing and market access of the company's products.

Alterity Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Alterity Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Alterity Therapeutics shares outstanding

The number of shares was Alterity Therapeutics in 2023 — This indicates how many shares 2.428 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Alterity Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Alterity Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Alterity Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Alterity Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Alterity Therapeutics.

Eulerpool ESG Scorecard© for the Alterity Therapeutics stock

Eulerpool World ESG Rating (EESG©)

56/ 100

🌱 Environment

58

👫 Social

78

🏛️ Governance

33

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees67
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Alterity Therapeutics list of shareholders

%
Name
Stocks
Change
Date
3.44659 % Regal Funds Management Pty. Ltd.183,370,294183,370,2941/30/2024
2.15326 % Life Biosciences LLC114,560,553-30,676,86010/31/2022
0.72470 % Jagen Pty. Ltd.38,556,49708/28/2023
0.39552 % Pandey (Anurag)21,042,90408/28/2023
0.36686 % Nguyen (Huy)19,518,43619,518,4368/28/2023
0.33853 % Kempler (Geoffrey Paul)18,011,00006/30/2023
0.33832 % Gunes (Elif Ceren)18,000,0005,000,0008/28/2023
0.33132 % Seton (Andrew Mark Wilmot)17,627,3331,138,7358/28/2023
0.29400 % Rentuk Shore Pty. Ltd.15,641,71908/28/2023
0.29113 % Au (Buu Lan)15,489,01008/28/2023
1
2

Alterity Therapeutics Executives and Management Board

Dr. David Stamler62
Alterity Therapeutics Chief Executive Officer
Compensation 1.65 M
Ms. Kathryn Andrews56
Alterity Therapeutics Chief Financial Officer
Compensation 367,556
Mr. Geoffrey Kempler68
Alterity Therapeutics Non-Executive Chairman of the Board (since 1997)
Compensation 313,300
Mr. Phillip Hains63
Alterity Therapeutics Chief Financial Officer, Company Secretary
Compensation 100,000
Mr. Lawrence Gozlan44
Alterity Therapeutics Non-Executive Director
Compensation 70,000
1
2

Alterity Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
HSBC Holdings Stock
HSBC Holdings
SupplierCustomer-0,070,690,06-0,61-0,81-0,66
1

Most common questions regarding Alterity Therapeutics

What values and corporate philosophy does Alterity Therapeutics represent?

Alterity Therapeutics Ltd represents values of innovation, scientific rigor, and collaboration in the field of neurodegenerative diseases. The company's corporate philosophy emphasizes a patient-centric approach, aiming to develop transformative treatments for disorders like Parkinson's and Alzheimer's disease. Alterity Therapeutics fosters a culture of excellence and ethical behavior, prioritizing the well-being of patients and supporting their families. By investing in cutting-edge research and partnering with experts, Alterity Therapeutics seeks to provide novel therapies that can improve the quality of life for individuals affected by these devastating conditions.

In which countries and regions is Alterity Therapeutics primarily present?

Alterity Therapeutics Ltd is primarily present in Australia and the United States.

What significant milestones has the company Alterity Therapeutics achieved?

Alterity Therapeutics Ltd, a leading biotechnology company, has achieved several significant milestones in its journey. The company has successfully developed innovative therapies and drug candidates, revolutionizing the treatment of neurological disorders. Alterity Therapeutics Ltd has advanced its flagship drug, PBT434, through multiple clinical trials, demonstrating promising results in treating Parkinson's and other neurodegenerative diseases. The company has also secured valuable partnerships with renowned institutions and researchers, further validating its scientific approach. Leveraging its expertise in targeting neurodegeneration, Alterity Therapeutics Ltd continues to make groundbreaking progress in improving patient outcomes and has garnered recognition from the scientific and investor community alike.

What is the history and background of the company Alterity Therapeutics?

Alterity Therapeutics Ltd is a biotechnology company focused on the development of novel therapies for the treatment of neurodegenerative diseases. Founded in 1997, Alterity has been dedicated to researching and developing drug candidates targeting Parkinson's and Alzheimer's diseases. The company's lead candidate, PBT2, has shown promising results in pre-clinical and clinical trials, demonstrating its potential to treat neurodegeneration by reducing brain metal imbalances. With an experienced team and strategic partnerships, Alterity Therapeutics Ltd is committed to advancing their innovative therapies to address the growing need for effective treatments in the field of neurodegenerative diseases.

Who are the main competitors of Alterity Therapeutics in the market?

The main competitors of Alterity Therapeutics Ltd in the market include major pharmaceutical companies such as Biogen, Pfizer, and Novartis. These companies also focus on developing treatments and therapies for neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease. Alterity Therapeutics Ltd competes with these industry leaders in terms of research, development, and commercialization of innovative drug candidates targeting neurodegenerative disorders.

In which industries is Alterity Therapeutics primarily active?

Alterity Therapeutics Ltd is primarily active in the pharmaceutical and biotechnology industries. As a leading company, Alterity Therapeutics specializes in developing innovative therapies for neurodegenerative diseases, particularly Parkinson's and Alzheimer's. With a focus on altering the course of these debilitating conditions, Alterity Therapeutics conducts extensive research and collaborates with healthcare professionals and industry experts to bring about groundbreaking treatments. By leveraging its expertise in drug development and neurology, Alterity Therapeutics continues to make significant contributions to the field of healthcare, offering hope and improving the lives of patients worldwide.

What is the business model of Alterity Therapeutics?

Alterity Therapeutics Ltd operates as a biotechnology company. The business model of Alterity Therapeutics is focused on the development and commercialization of novel therapeutics for neurodegenerative diseases. The company primarily specializes in the research and development of drugs targeting Parkinson's and Alzheimer's diseases. Alterity Therapeutics aims to identify and develop small molecules that can effectively treat neurological disorders by targeting misfolded proteins, specifically alpha-synuclein and tau. By addressing these protein abnormalities, Alterity Therapeutics seeks to provide innovative treatment options for patients suffering from neurodegenerative diseases.

What is the P/E ratio of Alterity Therapeutics 2024?

The Alterity Therapeutics P/E ratio is -0.58.

What is the P/S ratio of Alterity Therapeutics 2024?

The Alterity Therapeutics P/S ratio is 41.1.

What is the AlleAktien quality score of Alterity Therapeutics?

The AlleAktien quality score for Alterity Therapeutics is 4/10.

What is the revenue of Alterity Therapeutics 2024?

The Alterity Therapeutics revenue is 268,420 AUD.

How high is the profit of Alterity Therapeutics 2024?

The Alterity Therapeutics profit is -19.12 M AUD.

What is the business model of Alterity Therapeutics

Alterity Therapeutics Ltd is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company is headquartered in Australia and has a branch in the USA. The business model of Alterity Therapeutics is based on the discovery, development, and commercialization of therapies for diseases such as Parkinson's, Alzheimer's, and multiple sclerosis. The company has a proprietary technology platform called "Stellate Therapies" that is based on the discovery of novel compounds capable of detecting and eliminating abnormally folded proteins in the brain. Alterity Therapeutics is also proud to have a strong pipeline of product candidates. Their leading candidate is currently ATH434, which is in a phase II study for the treatment of Parkinson's. The drug aims to break down the protein alpha-synuclein, which occurs in abnormal amounts in Parkinson's patients, slowing down the progression of the disease. In addition to ATH434, the company is working on the development of other Stellate candidates, including ATH554 and ATH555, which are in preclinical studies. These candidates target other protein-related diseases such as Alzheimer's and ALS. The business model of Alterity Therapeutics is not only limited to the development of new therapies but also to collaborating with other companies. The company has partnerships with leading pharmaceutical companies such as Takeda, Sanofi, and Axovant Sciences to work together on therapy development. Alterity Therapeutics also has a research and development department focused on advancing the company's knowledge and technology platform. It is also determined to enter into new partnerships to explore further opportunities for therapy development and commercialization. Overall, the business model of Alterity Therapeutics is aimed at giving patients with neurodegenerative diseases new hope. Through the development of innovative therapies and collaboration with other companies, the goal is to improve the lives of people affected by these diseases.

What is the Alterity Therapeutics dividend?

Alterity Therapeutics pays a dividend of 0 AUD distributed over payouts per year.

How often does Alterity Therapeutics pay dividends?

The dividend cannot currently be calculated for Alterity Therapeutics or the company does not pay out a dividend.

What is the Alterity Therapeutics ISIN?

The ISIN of Alterity Therapeutics is AU0000043945.

What is the Alterity Therapeutics WKN?

The WKN of Alterity Therapeutics is A2PHDZ.

What is the Alterity Therapeutics ticker?

The ticker of Alterity Therapeutics is ATH.AX.

How much dividend does Alterity Therapeutics pay?

Over the past 12 months, Alterity Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alterity Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Alterity Therapeutics?

The current dividend yield of Alterity Therapeutics is .

When does Alterity Therapeutics pay dividends?

Alterity Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alterity Therapeutics?

Alterity Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Alterity Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alterity Therapeutics located?

Alterity Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alterity Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alterity Therapeutics from 9/25/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/25/2024.

When did Alterity Therapeutics pay the last dividend?

The last dividend was paid out on 9/25/2024.

What was the dividend of Alterity Therapeutics in the year 2023?

In the year 2023, Alterity Therapeutics distributed 0 AUD as dividends.

In which currency does Alterity Therapeutics pay out the dividend?

The dividends of Alterity Therapeutics are distributed in AUD.

All fundamentals about Alterity Therapeutics

Our stock analysis for Alterity Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alterity Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.